Saturday, 31 October 2026European Markets

PROACTIS Stock Plummets Over 24% As Trading Day Ends

Loading stream...

(vianews) - at 15:24 est on friday, proactis sa (cac 40: proac.pa) shares experienced a dramatic 24.14% decrease to eur0.04 at 15:24, following an uptrend. meanwhile, cac 40 was showing positive momentum, climbing 0.49% to eur8,201.69 - representing its third consecutive day of gains! proactis sa previously closed at eur0.06, 54.33% below its 52-week high of eur0.13.

about proactis sa

proactis sa is a leading provider of source-to-pay software solutions, offering businesses an all-encompassing platform to gain greater control of their spending. with its solutions tailored towards procurement, the company meets the needs of purchasing professionals by equipping them with tools necessary for routine goods and services, capital goods purchases and major projects. proactis sa provides various services, such as invoice capture, system administration, supplier onboarding and tail spent management. proactis' solutions seamlessly integrate with various erp and financial systems, making them an efficient and versatile choice for businesses of all sizes. headquartered in suresnes, france formerly known as hubwoo is part of proactis euro hedgeco limited and operates under its management.

yearly analysis

based on available information, proactis sa's stock is currently trading below its 52-week low of eur0.04 which signifies it has reached its lowest point during this year. keep in mind that stock prices can be volatile and vary drastically over short periods. therefore it is wise to conduct a comprehensive examination of proactis sa's finances, industry trends, and other relevant factors before making any investment decisions.

technical analysis

proactis sa's stock price has experienced a dramatic decrease, falling well below both its 50-day and 200-day moving averages. this may represent an opportunity for investors to capitalize on its undervaluation. volume has also significantly increased; today's reported volume was 35,501 which is 277.51% above its average volume of 9,404 and could signal greater interest or potential buying pressure in the near future. but proactis sa has also experienced considerable fluctuation over the past several weeks and months, with intraday variation averages currently standing at negative 0.01%, negative 1.49%, and positive 9.86%; its highest amplitude of average volatility being 1.76% for one week, 12.28% for one month, and 9.86% for three quarters. according to the stochastic oscillator, proactis sa's stock may currently be considered oversold (=20), which could suggest it has become undervalued and may rebound in the near future. overall, proactis sa's current stock price reveals an inconsistent picture for investors; with potential buying opportunities due to undervaluation but significant uncertainty and volatility arising in its short-term outlook. therefore, investors must carefully consider their investment strategy and risk tolerance before taking any decisions regarding this stock.

quarter analysis

revenue growth desfasoarted over the last twelve months by 3.6% to 14.11 million.

equity analysis

based on available data, proactis sa has posted an earnings per share (eps) for its trailing twelve month period of eur-0.01, indicating negative earnings per share over this timeframe. furthermore, proactis' return on equity (roe) was negative over the same period -3.88% which suggests that proactis did not generate profits for its shareholders relative to their equity investment in proactis. these numbers may cause concern among potential investors since negative eps and roe figures can indicate financial instability or lack of profitability of a company; it's wise to conduct further analyses before making investment decisions based on this information alone.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com